Molecular Alterations in AML

12345678910111213141516
Across
  1. 2. KMT2A partner associated with megakaryoblastic leukemia
  2. 3. Associated with CD2 expression in APL
  3. 5. Inv(16) or t(16;16)
  4. 7. Used to uncover cryptic translocations
  5. 8. Aggressive, typically with complex karyotype
  6. 11. AML-MR by ICC, may express B-lineage markers
  7. 12. APL subtype frequently CD34-positive
  8. 14. Blasts with cup-shape nuclei
  9. 16. WHO still requires 20% blasts when mutated
Down
  1. 1. Resistant to ATRA
  2. 4. Multilineage dysplasia and basophilia
  3. 5. bZIP domain mutations have good prognosis.
  4. 6. Gene commonly co-mutated in AML, does not define a unique AML subtype, intermediate prognosis by ELN 2022
  5. 9. Rearranged in AML with broad cytomorphologic features, typically monocytic, often cryptically rearranged
  6. 10. High blast count, APL-like morphology, dysplasia
  7. 13. Core binding factor alpha subunit rearranged in AML
  8. 15. Rearranged in AML, resulting in decreased GATA2 expression